Several studies reported higher response rates and improved PFS in patients in breast cancer with high TMB, who received PD-1/PD-L1 immunotherapy (Barroso-Sousa et al., 2020; Karn et al., 2020; Garrido-Castro et al., 2021). This evidence concerns the gene CD274 and breast carcinoma.